(Q38211244)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Current assessment of polo-like kinases as anti-tumor drug targets (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Sandra N Craig

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Campbell McInnes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

English

0 references

publication date

12 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

773-789

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24819909%20AND%20SRC:MED&resulttype=core&format=json

PLK1 as an oncology target: current status and future potential

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 is essential for early embryonic development and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase-2 is required for centriole duplication in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Caenorhabditis elegans contains structural homologs of human prk and plk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Regulation of PTEN stability and activity by Plk3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

SAK/PLK4 is required for centriole duplication and flagella development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Cep152 interacts with Plk4 and is required for centriole duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

The Polo kinase Plk4 functions in centriole duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Sak/Plk4 and mitotic fidelity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Human Plk4 phosphorylates Cdc25C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Gene expression patterns in heterozygous Plk4 murine embryonic fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

From Plk1 to Plk5: functional evolution of polo-like kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Normal cells, but not cancer cells, survive severe Plk1 depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Enabling and disabling polo-like kinase 1 inhibition through chemical genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Mechanisms of p53-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 regulates mitotic arrest after UV irradiation through dephosphorylation of p53 and inducing p53 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Plk1-mediated phosphorylation of Topors regulates p53 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 (Plk1) in non-melanoma skin cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

p53-dependent repression of polo-like kinase-1 (PLK1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

The functions and regulation of the PTEN tumour suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.918100